{"id":1143,"date":"2018-12-03T15:38:56","date_gmt":"2018-12-03T15:38:56","guid":{"rendered":"http:\/\/www.visioeng.it\/?page_id=1143"},"modified":"2021-07-03T16:16:41","modified_gmt":"2021-07-03T16:16:41","slug":"new-methods-and-device-for-the-management-of-keratoconus","status":"publish","type":"page","link":"https:\/\/www.visioeng.it\/en\/new-methods-and-device-for-the-management-of-keratoconus\/","title":{"rendered":"New methods and device for the management of keratoconus"},"content":{"rendered":"<div class=\"aux-vc-wrapper\" >[vc_section][vc_row][vc_column][vc_column_text]\n<h1 style=\"text-align: center;\">New methods and device for the management of keratoconus<\/h1>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row gap=&#8221;30&#8243;][vc_column offset=&#8221;vc_col-lg-offset-1 vc_col-lg-5 vc_col-md-offset-2 vc_col-md-8 vc_col-sm-offset-0 vc_col-xs-12&#8243;][vc_column_text]<section class=\"aux-bus2-image-green-gradiant-reverse aux-bus2-image-radius-10px widget-container aux-widget-image aux-alignnone aux-parent-au7fbcfda2\" style=\"\" >\n    <div class=\"aux-media-hint-frame \">\n        <div class=\"aux-media-image \" >\n        \n            \n\n                            <div class='aux-hover-scale-circle-plus'>\n                    <span class='aux-symbol-plus'><\/span>\n                    <span class='aux-symbol-circle'><\/span>\n                <\/div>\n            \n            <img width=\"777\" height=\"648\" src=\"https:\/\/www.visioeng.it\/wp-content\/uploads\/terapia-cornea-1-777x697.jpg\" class=\"aux-attachment aux-featured-image aux-attachment-id-673\" alt=\"terapia cornea\" srcset=\"https:\/\/www.visioeng.it\/wp-content\/uploads\/terapia-cornea-1-200x179.jpg 200w,https:\/\/www.visioeng.it\/wp-content\/uploads\/terapia-cornea-1-500x449.jpg 500w,https:\/\/www.visioeng.it\/wp-content\/uploads\/terapia-cornea-1-768x689.jpg 768w,https:\/\/www.visioeng.it\/wp-content\/uploads\/terapia-cornea-1-777x697.jpg 777w\" data-ratio=\"1.11\" data-original-w=\"892\" sizes=\"(max-width:479px) 480px,(max-width:767px) 768px,(max-width:1023px) 1024px,777px\" \/>            \n                <\/div>\n    <\/div>\n\n<\/section><!-- widget-container -->[\/vc_column_text][\/vc_column][vc_column el_class=&#8221;aux-bus2-projects-column&#8221; offset=&#8221;vc_col-lg-offset-0 vc_col-lg-5 vc_col-md-offset-2 vc_col-md-8 vc_col-sm-offset-0 vc_col-xs-12&#8243;][vc_column_text]<section class=\"aux-bus2-projects-text aux-bus2-green-btn aux-parallax widget-container aux-widget-text aux-parent-aud8de437c\" style=\"\" >        <div class=\"aux-widget-advanced-text aux-wrap-style-simple aux-ico-pos-top aux-text-left aux-text-resp-left aux-text-color-dark aux-text-widget-bg-center  \" style=\"background-color: #f9f9f9; \">\n        \n            \n            <div class=\"aux-text-inner aux-text-widget-content\">\n                                <div class=\"widget-content\">\n                                        \n<h3>Theranostics for keratoconus<\/h3>\n<div class=\"aux-bus2-title-divider\"><\/div>\n<p>\u00a0<\/p>\n<p>Vision Engineering Italy has designed the first available ophthalmic teranostic medical device<\/p>\n                <\/div>\n                            <\/div>\n        <\/div>\n                    <div class=\"aux-text-widget-footer\">\n                <div class=\"aux-border-shape-none \">\n                                <\/div>\n            <\/div>\n        \n<\/section><!-- widget-container -->[\/vc_column_text][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1532700143676{margin-bottom: 110px !important;}&#8221;][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Vision Engineering Italy has invented and patented the method and theranostic device that will personalize the corneal cross-linking treatment of keratoconus.[\/vc_column_text][vc_column_text]<div id=\"accordions-1137\" class=\"accordions-1137 accordions\">\r\n                <style type='text\/css'>\r\n        @media only screen and (min-width: 1024px ){\r\n            #accordions-1137 {\r\n                            width: 100%;\r\n                        }\r\n        }\r\n        @media only screen and ( min-width: 768px ) and ( max-width: 1023px ) {\r\n            #accordions-1137 {\r\n                            width: 100%;\r\n                        }\r\n        }\r\n        @media only screen and ( min-width: 0px ) and ( max-width: 767px ){\r\n            #accordions-1137 {\r\n                            width: 100%;\r\n                        }\r\n        }\r\n        #accordions-1137 {\r\n                            text-align: left;\r\n                                                position: relative;\r\n        }\r\n        #accordions-1137 .accordions-head{\r\n                    background:#1bb0ce none repeat scroll 0 0;\r\n                                    outline: none;\r\n        }\r\n        #accordions-1137 .accordions-head-title{\r\n                            color:#ffffff;\r\n                            font-size:14px;\r\n                }\r\n        #accordions-1137 .accordions-head-title-toggle{\r\n                    color:#ffffff;\r\n                            font-size:14px;\r\n                }\r\n        #accordions-1137 .accordions-head:hover .accordions-head-title{\r\n                    color:#ffffff;\r\n                }\r\n        #accordions-1137 .ui-state-active{\r\n                    background: #00b3c0;\r\n                    border: none;\r\n        }\r\n        #accordions-1137 .accordion-content{\r\n                                    color:#333333;\r\n                            font-size:13px;\r\n                                    border: none;\r\n        }\r\n        #accordions-1137 .accordion-icons{\r\n                        color:#565656;\r\n                                                                        margin:0px;\r\n                    }\r\n        #accordions-1137 .accordions-head:hover .accordion-icons span{\r\n                    }\r\n        #accordions-1137 {}\r\n#accordions-1137 .accordions-head{font-family: &quot;Ubuntu&quot;; font-size: 1.375em; letter-spacing: 0;\r\n    font-weight: 600;}\r\n#accordions-1137 .accordion-content{font-family: &quot;Roboto&quot;; font-size: 1em; color: #444; line-height: 1.5;\r\n    font-style: normal;}    <\/style>\r\n    <div class=\"items\">\r\n                        <div post_id=\"1137\" itemcount=\"0\" header_id=\"header-0\" id=\"header-0\" style=\"\" class=\"accordions-head head0 border-none\" toggle-text=\"\" main-text=\"Keratoconus and standard corneal cross-linking\">\r\n                                            <span id=\"accordion-icons-0\" class=\"accordion-icons\">\r\n                            <span class=\"accordion-icon-active accordion-plus\"><i class=\"fa fa-plus\"><\/i><\/span>\r\n                            <span class=\"accordion-icon-inactive accordion-minus\"><i class=\"fa fa-minus\"><\/i><\/span>\r\n                        <\/span>\r\n                        <span id=\"header-text-0\" class=\"accordions-head-title\">Keratoconus and standard corneal cross-linking<\/span>\r\n                                        <\/div>\r\n                <div class=\"accordion-content content0 \">\r\n                    <p>Keratoconus is a degenerative corneal disease; it is the primary cause of corneal transplantation in affects young people worldwide.<br \/>\nKeratoconus has been treated by riboflavin\/UV-A corneal cross-linking for more than ten years. Corneal cross-linking consists of instilling drops of riboflavin (vitamin B2) on the cornea, after corneal de-epithelialization, for about 30 minutes and then illuminating the tissue with an Ultraviolet lamp (UV-A) for 30 minutes. The purpose of the treatment is to stiffen the corneal tissue, which is weakened by the disease, through a chemical photo-polymerization process. Although the treatment is effective in more than half of cases, there are severe complications that may threaten corneal tissue.<\/p>\n                <\/div>\r\n                                <div post_id=\"1137\" itemcount=\"1\" header_id=\"header-1543850845790\" id=\"header-1543850845790\" style=\"\" class=\"accordions-head head1543850845790 border-none\" toggle-text=\"\" main-text=\"Transepithelial corneal cross-linking\">\r\n                                            <span id=\"accordion-icons-1543850845790\" class=\"accordion-icons\">\r\n                            <span class=\"accordion-icon-active accordion-plus\"><i class=\"fa fa-plus\"><\/i><\/span>\r\n                            <span class=\"accordion-icon-inactive accordion-minus\"><i class=\"fa fa-minus\"><\/i><\/span>\r\n                        <\/span>\r\n                        <span id=\"header-text-1543850845790\" class=\"accordions-head-title\">Transepithelial corneal cross-linking<\/span>\r\n                                        <\/div>\r\n                <div class=\"accordion-content content1543850845790 \">\r\n                    <p>Vision Engineering Italy is committed to developing new corneal cross-linking procedures that may be more safe and effective than standard treatment. In the last years, corneal cross-linking can be performed without removing the corneal epithelium, thus eliminating almost all the complications caused by standard treatment. The clinical outcomes of the first transepithelial procedures (so-called because the epithelium is not removed), however, were controversial, as many protocols showed not to be effective. The founders of Vision Engineering Italy participated in the development and validation of transepithelial corneal cross-linking with iontophoresis, the only transepithelial protocol which has been shown to be effective in controlled studies.<\/p>\n                <\/div>\r\n                                <div post_id=\"1137\" itemcount=\"2\" header_id=\"header-1543850847358\" id=\"header-1543850847358\" style=\"\" class=\"accordions-head head1543850847358 border-none\" toggle-text=\"\" main-text=\"Our project\">\r\n                                            <span id=\"accordion-icons-1543850847358\" class=\"accordion-icons\">\r\n                            <span class=\"accordion-icon-active accordion-plus\"><i class=\"fa fa-plus\"><\/i><\/span>\r\n                            <span class=\"accordion-icon-inactive accordion-minus\"><i class=\"fa fa-minus\"><\/i><\/span>\r\n                        <\/span>\r\n                        <span id=\"header-text-1543850847358\" class=\"accordions-head-title\">Our project<\/span>\r\n                                        <\/div>\r\n                <div class=\"accordion-content content1543850847358 \">\r\n                    <p>Vision Engineering Italy has developed an innovative UV-A device that assists the eye surgeon in real-time to perform corneal cross-linking with the aim of improving vision. The device is undergoing industrialization.<br \/>\nThe project is co-financed with European regional development funds<\/p>\n                <\/div>\r\n                    <\/div>\r\n    <script>\r\n        jQuery(document).ready(function($){accordions_active_index_1137 = [0];        })\r\n    <\/script><script type=\"application\/ld+json\">\r\n{\r\n    \"@context\": \"https:\/\/schema.org\",\r\n    \"@type\": \"FAQPage\",\r\n    \"mainEntity\": [{\r\n        \"@type\": \"Question\",\r\n        \"name\": \"Keratoconus and standard corneal cross-linking\",\r\n        \"acceptedAnswer\":{\r\n            \"@type\": \"Answer\",\r\n            \"text\": \"Keratoconus is a degenerative corneal disease; it is the primary cause of corneal transplantation in affects young people worldwide.\r\nKeratoconus has been treated by riboflavin\/UV-A corneal cross-linking for more than ten years. Corneal cross-linking consists of instilling drops of riboflavin (vitamin B2) on the cornea, after corneal de-epithelialization, for about 30 minutes and then illuminating the tissue with an Ultraviolet lamp (UV-A) for 30 minutes. The purpose of the treatment is to stiffen the corneal tissue, which is weakened by the disease, through a chemical photo-polymerization process. Although the treatment is effective in more than half of cases, there are severe complications that may threaten corneal tissue.\"\r\n            }\r\n        },{\r\n        \"@type\": \"Question\",\r\n        \"name\": \"Transepithelial corneal cross-linking\",\r\n        \"acceptedAnswer\":{\r\n            \"@type\": \"Answer\",\r\n            \"text\": \"Vision Engineering Italy is committed to developing new corneal cross-linking procedures that may be more safe and effective than standard treatment. In the last years, corneal cross-linking can be performed without removing the corneal epithelium, thus eliminating almost all the complications caused by standard treatment. The clinical outcomes of the first transepithelial procedures (so-called because the epithelium is not removed), however, were controversial, as many protocols showed not to be effective. The founders of Vision Engineering Italy participated in the development and validation of transepithelial corneal cross-linking with iontophoresis, the only transepithelial protocol which has been shown to be effective in controlled studies.\"\r\n            }\r\n        },{\r\n        \"@type\": \"Question\",\r\n        \"name\": \"Our project\",\r\n        \"acceptedAnswer\":{\r\n            \"@type\": \"Answer\",\r\n            \"text\": \"Vision Engineering Italy has developed an innovative UV-A device that assists the eye surgeon in real-time to perform corneal cross-linking with the aim of improving vision. The device is undergoing industrialization.\r\nThe project is co-financed with European regional development funds\"\r\n            }\r\n        }]\r\n}\r\n<\/script>    <script>\r\n        jQuery(document).ready(function($){\r\n            accordion_1137  = $(\"#accordions-1137 .items\").accordion({\r\n                event: \"click\",\r\n                collapsible:true,\r\n                heightStyle: \"content\",\r\n                animate: (\"swing\", 1000),\r\n                navigation: true,\r\n                active: 999,\r\n                            });\r\n        })\r\n    <\/script>\r\n                <\/div>[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_custom_heading text=&#8221;Publications&#8221; font_container=&#8221;tag:h2|text_align:left|color:%2300c1cf&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]\n<ul>\n<li><a href=\"\/wp-content\/uploads\/Theranostics_Journal_of_Biophotonics.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"> Lombardo G, Villari V, Micali NL, Leone N, Labate C, De Santo MP, Lombardo M. Non- invasive optical method for real-time assessment of intracorneal riboflavin concentration and efficacy of corneal cross-linking. J Biophotonics. 2018 Jul;11(7):e201800028.<\/a><\/li>\n<li><a href=\"#\"> Lombardo M, Lombardo G.Noninvasive real-time assessment of riboflavin consumption in standard and accelerated corneal crosslinking. J Cataract Refract Surg. 2018 Oct 22. pii: S0886-3350(18)30792-2.<\/a><\/li>\n<li>\n<div class=\"docsum-content\"><span class=\"docsum-authors full-authors\">Lombardo G, Serrao S, Lombardo M.<\/span>Comparison between standard and transepithelial corneal crosslinking using a theranostic UV-A device. <span class=\"docsum-journal-citation full-journal-citation\">Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):829-834. doi: 10.1007\/s00417-019-04595-6. Epub 2020 Jan 3.<\/span><\/div>\n<\/li>\n<\/ul>\n[\/vc_column_text][vc_custom_heading text=&#8221;Awards&#8221; font_container=&#8221;tag:h2|text_align:left|color:%2300c1cf&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]\n<ul>\n<li>Winner of the 8th China Innovation And Entrepreneurship<\/li>\n<li>Third Award at the China-Italy Best Startup showcase<\/li>\n<li>Winner of the National Roadshow of BioinItaly &#8211; StartUp Initiative &#8211; Healthcare &amp; Biomedical 2018<\/li>\n<li>Finalist at the Leonardo Start up 2017 Award<\/li>\n<li>Finalist of the first edition of the Open Innovative PMI Award<\/li>\n<li>Finalist at Unicredit BootCamp Startup-On-Stage 2017<\/li>\n<li>Winner of the Corporate Fast Track <em>Award of the 2016 Gaetano Marzotto Prize<\/em><\/li>\n<li>Winner of the IngDan Far East Development <em>Special Prize of the 2016 Gaetano Marzotto Prize<\/em><\/li>\n<\/ul>\n[\/vc_column_text][vc_empty_space][vc_custom_heading text=&#8221;The project has been co-funded with European funding&#8221; font_container=&#8221;tag:h4|text_align:center&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_single_image image=&#8221;1297&#8243; img_size=&#8221;medium&#8221; alignment=&#8221;center&#8221; style=&#8221;vc_box_shadow&#8221; onclick=&#8221;custom_link&#8221; link=&#8221;\/sviluppo-dispositivo-uv-a-di-teranostica-per-il-trattamento-del-cheratocono-lazio-innova\/&#8221;][vc_column_text]\n<p style=\"text-align: center;\"><section class=\"aux-bus2-projects-text aux-bus2-green-btn aux-parallax widget-container aux-widget-text aux-parent-au424fa715\" style=\"\" >        <div class=\"aux-widget-advanced-text aux-wrap-style-simple aux-ico-pos-top aux-text-left aux-text-resp-left aux-text-color-dark aux-text-widget-bg-center aux-text-no-content \" style=\"background-color: #ffffff; \">\n        \n            \n            <div class=\"aux-text-inner aux-text-widget-content\">\n                            <\/div>\n        <\/div>\n                    <div class=\"aux-text-widget-footer\">\n                <div class=\"aux-border-shape-none \">\n                                <\/div>\n            <\/div>\n        \n<\/section><!-- widget-container -->\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row disable_element=&#8221;yes&#8221; css=&#8221;.vc_custom_1536591420982{margin-bottom: 110px !important;}&#8221;][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Vision Engineering Italy ha inventato e brevettato Chromo4Vis, il dispositivo medico di teranostica che personalizzer\u00e0 il trattamento di cross-linking corneale per la cura del cheratocono.[\/vc_column_text][vc_tta_accordion style=&#8221;flat&#8221; shape=&#8221;square&#8221; color=&#8221;turquoise&#8221; active_section=&#8221;1&#8243; no_fill=&#8221;true&#8221;][vc_tta_section title=&#8221;Cheratocono e cross-linking corneale tradizionale&#8221; tab_id=&#8221;1536591402653-d41c686a-6de3&#8243;][vc_column_text]Il cheratocono \u00e8 una malattia degenerativa della cornea; interessa i giovani ed \u00e8 la prima causa di trapianto corneale negli under 45 in tutto il mondo.<\/p>\n<p>Da poco pi\u00f9 di dieci anni, il cheratocono pu\u00f2 essere trattato con il cross-linking corneale. Il cross-linking corneal consiste consiste nell\u2019instillare gocce di riboflavina (vitamina B2) sullo stroma corneale, dopo aver disepitelizzato un&#8217;area centrale della cornea, per circa 30 minuti e quindi nell\u2019illuminare il tessuto corneale con una lampada Ultravioletta (UV-A) per 30 minuti. Lo scopo del trattamento \u00e8 indurre un irrigidimento della cornea, indebolita dalla malattia stessa, mediante un processo chimico di foto-polimerizzazione. Nonostante il trattamento sia efficace in pi\u00f9 della met\u00e0 dei casi trattati, ha un tasso di complicanze superiore al 10%, che in qualche caso possono alterare l\u2019integrit\u00e0 del tessuto corneale.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=&#8221;Cross-linking corneale transepiteliale&#8221; tab_id=&#8221;1536591402810-e01269fc-b0fd&#8221;][vc_column_text]Vision Engineering Italy \u00e8 impegnata nello sviluppo di nuove procedure di cross-linking sempre pi\u00f9 efficaci e sicure rispetto al trattamento tradizionale. Da alcuni anni, il cross-linking pu\u00f2 essere eseguito senza rimuovere l\u2019epitelio corneale, eliminando cos\u00ec la quasi totalit\u00e0 delle complicanze associate all\u2019intervento. I risultati delle prime procedure transepiteliali (cos\u00ec dette perch\u00e9 non si rimuove l\u2019epitelio) sono tuttavia controversi, in quanto molti protocolli non sono efficaci. I fondatori di Vision Engineering Italy hanno partecipato allo sviluppo e validazione del cross-linking con iontoforesi, l\u2019unico protocollo transepiteliale efficace al pari della procedura tradizionale nei ragazzi di et\u00e0 superiore a 24 anni. Tuttavia, il cross-linking con iontoforesi non ha alcuna complicanza.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=&#8221;Il nostro progetto&#8221; tab_id=&#8221;1536591403003-ce76f2c3-32ce&#8221;][vc_row_inner][vc_column_inner width=&#8221;1\/4&#8243;][vc_single_image image=&#8221;783&#8243; img_size=&#8221;medium&#8221; onclick=&#8221;link_image&#8221;][\/vc_column_inner][vc_column_inner width=&#8221;3\/4&#8243;][vc_column_text]Vision Engineering Italy ha progettato un innovativo dispositivo di illuminazione UV-A che assiste il medico oculista in tempo reale ad eseguire il cross-linking corneale con 100% di efficacia.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_custom_heading text=&#8221;Pubblicazioni&#8221; font_container=&#8221;tag:h2|text_align:left|color:%2300c1cf&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]\n<ul>\n<li><a href=\"\/wp-content\/uploads\/Theranostics_Journal_of_Biophotonics.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Lombardo G, Villari V, Micali N, Leone N, Labate C, De Santo MP, Lombardo M. Non-invasive Optical Method for Real-time Assessment of Intracorneal Riboflavin Concentration And Efficacy Of Corneal Cross-linking. J Biophotonics 2018 Feb 16:e201800028.<\/a><\/li>\n<\/ul>\n[\/vc_column_text][vc_custom_heading text=&#8221;Premiazioni&#8221; font_container=&#8221;tag:h2|text_align:left|color:%2300c1cf&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text]\n<ul>\n<li>Vincitore del National Roadshow di BioinItaly \u2013 StartUp Initiative \u2013 Healthcare &amp; Biomedical<\/li>\n<li>Finalista al Premio Leonardo Start up 2017;<\/li>\n<li>Finalista della prima Edizione del Premio Open Innovative PMI;<\/li>\n<li>Finalista al BootCamp Startup-On-Stage<\/li>\n<li>Finalista della Unicredit start-lab 2017 \u2013 Life Science.<\/li>\n<li>Vincitore del <em>Premio Corporate Fast Track <\/em>del<em> Premio Gaetano Marzotto 2016<\/em>;<\/li>\n<li>Vincitore del <em>Premio Speciale IngDan Far East Development <\/em>del <em>Premio Gaetano Marzotto 2016<\/em>;<\/li>\n<\/ul>\n[\/vc_column_text][vc_empty_space][vc_custom_heading text=&#8221;Il progetto \u00e8 co-finanziato con i fondi europei di sviluppo regionale&#8221; font_container=&#8221;tag:h4|text_align:center&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_single_image image=&#8221;1297&#8243; img_size=&#8221;medium&#8221; alignment=&#8221;center&#8221; style=&#8221;vc_box_shadow&#8221; onclick=&#8221;custom_link&#8221; link=&#8221;\/sviluppo-di-apparato-di-teranostica-per-il-trattamento-del-cheratocono\/&#8221;][\/vc_column][\/vc_row][\/vc_section]\n<\/div> ","protected":false},"excerpt":{"rendered":"<p>[vc_section][vc_row][vc_column][vc_column_text] New methods and device for the management of keratoconus [\/vc_column_text][\/vc_column][\/vc_row][vc_row gap=&#8221;30&#8243;][vc_column offset=&#8221;vc_col-lg-offset-1 vc_col-lg-5 vc_col-md-offset-2 vc_col-md-8 vc_col-sm-offset-0 vc_col-xs-12&#8243;][vc_column_text][\/vc_column_text][\/vc_column][vc_column el_class=&#8221;aux-bus2-projects-column&#8221; offset=&#8221;vc_col-lg-offset-0 vc_col-lg-5 vc_col-md-offset-2 vc_col-md-8 vc_col-sm-offset-0 vc_col-xs-12&#8243;][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1532700143676{margin-bottom: 110px !important;}&#8221;][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Vision Engineering Italy has invented and patented the method and theranostic device that will personalize the corneal cross-linking treatment of keratoconus.[\/vc_column_text][vc_column_text][\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_custom_heading text=&#8221;Publications&#8221; font_container=&#8221;tag:h2|text_align:left|color:%2300c1cf&#8221; use_theme_fonts=&#8221;yes&#8221;][vc_column_text] Lombardo G, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/pages\/1143"}],"collection":[{"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/comments?post=1143"}],"version-history":[{"count":15,"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/pages\/1143\/revisions"}],"predecessor-version":[{"id":1602,"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/pages\/1143\/revisions\/1602"}],"wp:attachment":[{"href":"https:\/\/www.visioeng.it\/en\/wp-json\/wp\/v2\/media?parent=1143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}